Chris Gough
Biographic Data
| ID | 7446998 |
|---|---|
| NAME | Chris Gough |
| GIVEN NAMES | Chris |
| FAMILY NAME | Gough |
| SIGNATURE | GOUGH C |
| AFFILIATIONS | Canberra Alliance for Harm Minimisation and Advocacy Canberra Australia |
| VERIFIED | No |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
It’s Your Right – implementation and outcomes of a co-designed national Australian hepatitis C health promotion campaign
Ageing disgracefully with Jude Byrne
While most special sections in Drug and Alcohol Review are focused on a particular research topic, this collection is devoted posthumously to a person and her interests; Jude Byrne. Unique in her ability to lead work across advocacy, policy and research, Jude used her intelligence and living experience as a person who used drugs to influence policy and practice across the alcohol and other drug, blood-borne virus and community sectors. As we note…
Vale Jude Byrne
March marks the second anniversary of the passing of globally esteemed drug reform advocate Jude Byrne. Internationally, as well as in her home country of Australia, Jude was a courageous advocate for the marginalised. Identifying unapologetically as a person who injects drugs for over 40 years, Jude's living experience drove her human rights perspectives on drug use, law and health. While spearheading political change, Jude inspired generations …
I just thought that was the best thing for me to do at this point’
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers in this field also need greater access to information about depot buprenorphine to better address issues patients face during treatment. More research…
The feasibility of a drug consumption room in the Australian Capital Territory
PMD has received investigator-driven research funding from Gilead Sciences for work on hepatitis C unrelated to this work. PMD has served as an unpaid member of an Advisory Board for an intranasal naloxone product
No prominent works on this page.
The feasibility of a drug consumption room in the Australian Capital Territory
PMD has received investigator-driven research funding from Gilead Sciences for work on hepatitis C unrelated to this work. PMD has served as an unpaid member of an Advisory Board for an intranasal naloxone product
Vale Jude Byrne
March marks the second anniversary of the passing of globally esteemed drug reform advocate Jude Byrne. Internationally, as well as in her home country of Australia, Jude was a courageous advocate for the marginalised. Identifying unapologetically as a person who injects drugs for over 40 years, Jude's living experience drove her human rights perspectives on drug use, law and health. While spearheading political change, Jude inspired generations …
I just thought that was the best thing for me to do at this point’
Depot buprenorphine remains a promising treatment for OUD and offers potential to improve treatment adherence. Instances of restricted OAT choice and consumer concerns regarding a lack of agency must be addressed in order to enhance therapeutic relationships. Clinicians and other healthcare workers in this field also need greater access to information about depot buprenorphine to better address issues patients face during treatment. More research…
Ageing disgracefully with Jude Byrne
While most special sections in Drug and Alcohol Review are focused on a particular research topic, this collection is devoted posthumously to a person and her interests; Jude Byrne. Unique in her ability to lead work across advocacy, policy and research, Jude used her intelligence and living experience as a person who used drugs to influence policy and practice across the alcohol and other drug, blood-borne virus and community sectors. As we note…
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
It’s Your Right – implementation and outcomes of a co-designed national Australian hepatitis C health promotion campaign
HIV, Drug Use, Sexual Risk (4 works) · Medicine (4 works) · Opioid (3 works) · Opioid Use Disorder Treatment (3 works) · Psychology (3 works) · Engineering (2 works) · Family medicine (2 works) · Internal Medicine (2 works) · MEDLINE (2 works) · Psychiatry (2 works)